<?xml version="1.0" encoding="UTF-8"?>
<p id="par0285">Bevacizumab is an approved treatment for multiple cancers. It is a humanized monoclonal antibody that prevents the association between vascular endothelial growth factor (VEGF) and endothelial receptors Flt-1 and KDR, and it may reduce the levels of VEGF caused by hypoxia and severe inflammation. Eventually, it might suppress the edema in patients with COVID-19. Bevacizumab is currently being tested in a Chinese randomized controlled trial [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0345" ref-type="bibr">69</xref>].
</p>
